Novartis Aktie

126,00 EUR -2,00 EUR -1,56 %

18:17:17

STU

148,65 USD -2,37 USD -1,57 %

18:28:09

BTT

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

KGV19,02Div. Rendite2,23%

WKN907122

ISINUS66987V1098

SymbolNVS

Novartis Aktien News

Sortieren:Datum Meistgelesen

17.04.26MotleyFoolBetter Pharma Dividend Stock: Novartis vs. Merck

14.04.26ZacksAre Medical Stocks Lagging Alcon (ALC) This Year?

09.04.26Dow JonesPress Release: Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by ...

WerbungNovartis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

09.04.26Dow JonesPress Release: Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by ...

08.04.26ZacksAlcon Stock Gains Following the Launch of Clareon TruPlus at ASCRS

29.03.26Dow JonesPress Release: Novartis IgAN data in New England -2-

29.03.26Dow JonesPress Release: Novartis IgAN data in New England Journal of Medicine show Fabhalta(R) slowed kidney function decline by 49.3%

27.03.26ZacksNovartis Bolsters Immunology Pipeline With Excellergy Deal

27.03.26BenzingaNovartis Bets $2 Billion To Deepen Allergy Drug Pipeline

27.03.26Business TimesNovartis to buy US-based biotech firm Excellergy for up to US$2 billion

27.03.26RTE.ieNovartis to buy Excellergy for up to $2 billion

27.03.26Dow JonesPress Release: Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

23.03.26Dow JonesPress Release: Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

20.03.26ZacksNovartis Strikes $3B Oncology Deal for Breast Cancer Asset

20.03.26BenzingaNovartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug

20.03.26Dow JonesPress Release: Novartis agrees to acquire a pan-mutant-selective PI3KALPHA> inhibitor, strengthening its breast cancer pipeline

16.03.26BenzingaNovartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

13.03.26Dow JonesPress Release: Novartis Cosentyx(R) receives FDA -2-

13.03.26Dow JonesPress Release: Novartis Cosentyx(R) receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

09.03.26BenzingaWhat Analysts Are Saying About Alcon Stock

05.03.26BenzingaAlcon Earnings Report: Q4 Overview

02.03.26ZacksIs Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

02.03.26BenzingaWhat's Driving the Market Sentiment Around Novartis AG?

28.02.26BenzingaSecond HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement

27.02.26Dow JonesPress Release: Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

27.02.26Dow JonesPress Release: Novartis receives positive CHMP -2-

27.02.26Dow JonesPress Release: Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

25.02.26ZacksWhy Alcon (ALC) is a Top Growth Stock for the Long-Term

25.02.26MotleyFoolAlcon (ALC) Q4 2025 Earnings Call Transcript

25.02.26Dow JonesPress Release: Novartis to build new radioligand therapy site in Denton, Texas, delivering more next--generation treatments to patients

25.02.26ZacksAlcon (ALC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

24.02.26MotleyFoolCould Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?

24.02.26Dow JonesPress Release: Novartis: New real--world data -2-

24.02.26Dow JonesPress Release: Novartis: New real--world data reinforce earlier use of Pluvicto(TM) before chemotherapy in metastatic castration-resistant prostate cancer

23.02.26BenzingaEarnings Preview: Alcon

23.02.26Dow JonesPress Release: Novartis presents Rhapsido(R) (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

22.02.26MotleyFoolNovartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades

19.02.26ZacksGear Up for Alcon (ALC) Q4 Earnings: Wall Street Estimates for Key Metrics

18.02.26Dow JonesPress Release: Novartis remibrutinib first -2-

18.02.26Dow JonesPress Release: Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.